SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-19-017969
Filing Date
2019-05-09
Accepted
2019-05-09 16:07:12
Documents
93
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q akba-10q_20190331.htm 10-Q 3234680
2 EX-31.1 akba-ex311_6.htm EX-31.1 17689
3 EX-31.2 akba-ex312_8.htm EX-31.2 17687
4 EX-32.1 akba-ex321_7.htm EX-32.1 12241
  Complete submission text file 0001564590-19-017969.txt   12927149

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT akba-20190331.xml EX-101.INS 3098442
6 XBRL TAXONOMY EXTENSION SCHEMA akba-20190331.xsd EX-101.SCH 94915
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE akba-20190331_cal.xml EX-101.CAL 89712
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE akba-20190331_def.xml EX-101.DEF 349299
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE akba-20190331_lab.xml EX-101.LAB 635604
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akba-20190331_pre.xml EX-101.PRE 535183
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36352 | Film No.: 19810544
SIC: 2834 Pharmaceutical Preparations